losartan has been researched along with Kidney Failure in 41 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of losartan (MK-954) and its metabolite E3174." | 9.08 | The pharmacokinetics of losartan in renal insufficiency. ( Furtek, CI; Gehr, TW; Halstenson, CE; Keane, WF; Lipschutz, K; Lo, MW; Ritter, MA; Shahinfar, S; Shaw, WC; Sica, DA, 1995) |
| " The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency." | 7.73 | Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. ( Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006) |
| "We studied, in rats with secondary biliary cirrhosis and sham-operated rats, the effect of 0." | 5.33 | Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Neef, M; Sauerbruch, T; Schepke, M; Shiozawa, T; Trebicka, J, 2005) |
| " Data from the Renoprotection of Optimal Antiproteinuric Doses (ROAD) trial were used to examine the contribution of the antiproteinuric effect of benazepril and losartan on renal outcome (the primary composite end point of doubling of serum creatinine and end-stage renal disease or death) in 339 Chinese nondiabetic CKD patients with overt proteinuria and renal insufficiency." | 5.15 | High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease. ( Fu, BL; Hou, FF; Liang, M; Xie, D; Zhang, X, 2011) |
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| "To determine the effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of losartan (MK-954) and its metabolite E3174." | 5.08 | The pharmacokinetics of losartan in renal insufficiency. ( Furtek, CI; Gehr, TW; Halstenson, CE; Keane, WF; Lipschutz, K; Lo, MW; Ritter, MA; Shahinfar, S; Shaw, WC; Sica, DA, 1995) |
| "Losartan, the first potent and specific AT1 receptor antagonist, is orally active with a long duration of action and therefore has potential for treatment of chronic diseases, such as hypertension and heart failure." | 4.79 | The preclinical basis of the therapeutic evaluation of losartan. ( Chiu, AT; Smith, RD; Timmermans, PB; Wong, PC, 1995) |
| "We investigated the role of angiotensin II and endothelin-1 using the angiotensin AT1 receptor antagonist losartan and the endothelin ETA receptor antagonist atrasentan, in malignant hypertension and renal failure and damage induced by nitric oxide (NO) synthase inhibition in Harlan Sprague-Dawley (SD) rats." | 3.75 | Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. ( Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F, 2009) |
| "This article presents clinical data which suggest that the current dosage of losartan 50 to 100 mg/day may not be the optimum in many cases, especially if used as monotherapy in the treatment of proteinuria and we may have to increase to 200 mg/day." | 3.73 | ATRA therapy restores normal renal function and renal reserve and prevents renal failure. ( Chan, CM; Lau, YK; Wong, KS; Woo, KT, 2005) |
| " (3) Five clinical trials have evaluated angiotensin II receptor antagonists (candesartan, losartan and valsartan) in terms of their effect on mortality and on the risk of clinical deterioration in patients with symptomatic heart failure, but without severe renal failure, hyperkalemia or hypotension." | 3.73 | Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. ( , 2005) |
| " The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency." | 3.73 | Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency. ( Fujita, T; Kumasaka, R; Murakami, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shimada, M; Shirato, K; Yamabe, H, 2006) |
| " We report a premature infant born to a 41-year-old mother with a long history of infertility who had received losartan therapy for hypertension throughout an undetected pregnancy." | 3.73 | Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant. ( Bass, JK; Faix, RG, 2006) |
| " Safety was assessed in both studies by the incidence of adverse experiences." | 2.71 | Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. ( Dickson, TZ; Lin, CC; Lo, MW; Ramjit, D; Ritter, MA; Shahinfar, S; Snavely, D; Zagrobelny, J, 2003) |
| "Losartan-induced acute renal failure may occur in patients sensitive to reduced renal plasma flow." | 2.40 | Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. ( Esmail, ZN; Loewen, PS, 1998) |
| "Treatment with losartan significantly attenuated aortic AS, inhibited ER stress and reduced aortic inflammation." | 1.46 | Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation. ( Gan, H; Tang, W; Yang, J; Yu, X; Zhang, X, 2017) |
| "Treatment with losartan for MI rats significantly attenuated upregulated AT1R but not AT2R." | 1.39 | Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure. ( Cai, M; Chen, Y; Geng, D; Mai, Z; Wang, J; Wen, Z, 2013) |
| "Treatment with losartan significantly attenuated desmin- and p16(ink4a)-positive podocytes, restored podocin mRNA expression, and decreased blood cystatin C levels." | 1.39 | Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction. ( Cai, MY; Chen, YX; Geng, DF; Huang, H; Jin, DM; Mai, Z; Wang, JF; Wen, ZZ, 2013) |
| "Captopril and losartan were equally effective as mitigators, with DMFs of 1." | 1.37 | Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. ( Cohen, EP; Fish, BL; Moulder, JE, 2011) |
| "We studied, in rats with secondary biliary cirrhosis and sham-operated rats, the effect of 0." | 1.33 | Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Neef, M; Sauerbruch, T; Schepke, M; Shiozawa, T; Trebicka, J, 2005) |
| "Fonsartan and losartan treatment totally abolished these effects." | 1.32 | Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats. ( Grötsch, H; Hropot, M; Langer, KH; Linz, W; Wiemer, G, 2003) |
| "We report a case of IgA nephropathy with renal failure in which the deterioration of renal function was inhibited by the addition of angiotensin II receptor blocker (ARB) losartan." | 1.31 | Progression of renal failure delayed by use of losartan in a case of IgA nephropathy. ( Iseki, K; Takishita, S, 2002) |
| "Kidney failure is associated with changes in renal vascular responses to angiotensin (Ang) II." | 1.31 | Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. ( Bautista, R; Escalante, B; Hernández, J; Oyekan, A; Sánchez, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (19.51) | 18.2507 |
| 2000's | 22 (53.66) | 29.6817 |
| 2010's | 11 (26.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eltablawy, N | 1 |
| Ashour, H | 1 |
| Rashed, LA | 1 |
| Hamza, WM | 1 |
| Soni, H | 1 |
| Peixoto-Neves, D | 1 |
| Olushoga, MA | 1 |
| Adebiyi, A | 1 |
| Wen, Z | 2 |
| Cai, M | 1 |
| Mai, Z | 2 |
| Chen, Y | 1 |
| Geng, D | 1 |
| Wang, J | 1 |
| Wen, ZZ | 1 |
| Cai, MY | 1 |
| Jin, DM | 1 |
| Chen, YX | 1 |
| Huang, H | 1 |
| Geng, DF | 1 |
| Wang, JF | 1 |
| Rossignol, P | 1 |
| Dobre, D | 1 |
| Gregory, D | 1 |
| Massaro, J | 1 |
| Kiernan, M | 1 |
| Konstam, MA | 1 |
| Zannad, F | 1 |
| Rosendahl, A | 1 |
| Niemann, G | 1 |
| Lange, S | 1 |
| Ahadzadeh, E | 1 |
| Krebs, C | 1 |
| Contrepas, A | 1 |
| van Goor, H | 1 |
| Wiech, T | 1 |
| Bader, M | 1 |
| Schwake, M | 1 |
| Peters, J | 1 |
| Stahl, R | 1 |
| Nguyen, G | 1 |
| Wenzel, UO | 1 |
| Srisawat, U | 1 |
| Kongrat, S | 1 |
| Muanprasat, C | 1 |
| Chatsudthipong, V | 1 |
| Mao, W | 1 |
| Zhang, L | 2 |
| Zou, C | 1 |
| Li, C | 1 |
| Wu, Y | 2 |
| Su, G | 1 |
| Guo, X | 1 |
| Lu, F | 1 |
| Lin, Q | 1 |
| Wang, L | 1 |
| Bao, K | 1 |
| Xu, P | 1 |
| Zhao, D | 1 |
| Peng, Y | 1 |
| Liang, H | 1 |
| Lu, Z | 1 |
| Gao, Y | 1 |
| Jie, X | 1 |
| Liu, X | 1 |
| Yang, J | 1 |
| Zhang, X | 2 |
| Yu, X | 1 |
| Tang, W | 1 |
| Gan, H | 1 |
| Timmermans, PB | 1 |
| Wong, PC | 1 |
| Chiu, AT | 1 |
| Smith, RD | 1 |
| Sica, DA | 1 |
| Lo, MW | 2 |
| Shaw, WC | 1 |
| Keane, WF | 1 |
| Gehr, TW | 1 |
| Halstenson, CE | 1 |
| Lipschutz, K | 1 |
| Furtek, CI | 1 |
| Ritter, MA | 2 |
| Shahinfar, S | 2 |
| Susic, D | 1 |
| Zhou, X | 1 |
| Frohlich, ED | 1 |
| Therrien, F | 1 |
| Lemieux, P | 1 |
| Bélanger, S | 1 |
| Agharazii, M | 1 |
| Lebel, M | 1 |
| Larivière, R | 1 |
| Xie, D | 1 |
| Hou, FF | 1 |
| Fu, BL | 1 |
| Liang, M | 1 |
| Moulder, JE | 1 |
| Cohen, EP | 1 |
| Fish, BL | 1 |
| Leu, JG | 1 |
| Huang, CM | 1 |
| Kao, SJ | 1 |
| Jiang, WW | 1 |
| Yoshitani, T | 1 |
| Yagi, H | 1 |
| Inotsume, N | 1 |
| Yasuhara, M | 1 |
| Iseki, K | 1 |
| Takishita, S | 1 |
| Hropot, M | 1 |
| Langer, KH | 1 |
| Wiemer, G | 1 |
| Grötsch, H | 1 |
| Linz, W | 1 |
| Kööbi, P | 1 |
| Kalliovalkama, J | 1 |
| Jolma, P | 1 |
| Rysä, J | 1 |
| Ruskoaho, H | 1 |
| Vuolteenaho, O | 1 |
| Kähönen, M | 1 |
| Tikkanen, I | 1 |
| Fan, M | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 1 |
| Dickson, TZ | 1 |
| Zagrobelny, J | 1 |
| Lin, CC | 1 |
| Snavely, D | 1 |
| Ramjit, D | 1 |
| Mathur, S | 1 |
| Brown, CA | 1 |
| Dietrich, UM | 1 |
| Munday, JS | 1 |
| Newell, MA | 1 |
| Sheldon, SE | 1 |
| Cartier, LM | 1 |
| Brown, SA | 1 |
| Scaglione, R | 1 |
| Argano, C | 1 |
| Corrao, S | 1 |
| Di Chiara, T | 1 |
| Licata, A | 1 |
| Licata, G | 1 |
| Woo, KT | 1 |
| Lau, YK | 1 |
| Chan, CM | 1 |
| Wong, KS | 1 |
| Heller, J | 2 |
| Trebicka, J | 1 |
| Shiozawa, T | 1 |
| Schepke, M | 1 |
| Neef, M | 1 |
| Hennenberg, M | 1 |
| Sauerbruch, T | 1 |
| Suganuma, E | 1 |
| Zuo, Y | 1 |
| Ayabe, N | 1 |
| Ma, J | 1 |
| Babaev, VR | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Ichikawa, I | 1 |
| Fogo, AB | 1 |
| Kon, V | 1 |
| Shoda, J | 1 |
| Kanno, Y | 1 |
| Suzuki, H | 1 |
| Osawa, H | 1 |
| Nakamura, N | 1 |
| Shirato, K | 1 |
| Nakamura, M | 1 |
| Shimada, M | 1 |
| Kumasaka, R | 1 |
| Murakami, R | 1 |
| Fujita, T | 1 |
| Yamabe, H | 1 |
| Okumura, K | 1 |
| Bass, JK | 1 |
| Faix, RG | 1 |
| Baumgart, P | 1 |
| Pollock, DM | 1 |
| Divish, BJ | 1 |
| Polakowski, JS | 1 |
| Opgenorth, TJ | 1 |
| Cervenka, L | 1 |
| Jelínek, F | 1 |
| Schwarzbeck, A | 1 |
| Wittenmeier, KW | 1 |
| Hällfritzsch, U | 1 |
| Esmail, ZN | 1 |
| Loewen, PS | 1 |
| Venkata, C | 1 |
| Ram, S | 1 |
| Fierro, G | 1 |
| Schulz, E | 1 |
| Bech, JN | 1 |
| Pedersen, EB | 1 |
| Müller, GA | 1 |
| Sorooshian, M | 1 |
| Olson, JL | 1 |
| Meyer, TW | 1 |
| Gupta, S | 1 |
| Dash, SC | 1 |
| Bhowmik, D | 1 |
| Mohanty, NK | 1 |
| Agarwal, SK | 1 |
| Tiwari, SC | 1 |
| Bautista, R | 1 |
| Sánchez, A | 1 |
| Hernández, J | 1 |
| Oyekan, A | 1 |
| Escalante, B | 1 |
3 reviews available for losartan and Kidney Failure
| Article | Year |
|---|---|
The preclinical basis of the therapeutic evaluation of losartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Disease M | 1995 |
Losartan as an alternative to ACE inhibitors in patients with renal dysfunction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Humans; Kidney; Losartan; Renal I | 1998 |
The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
9 trials available for losartan and Kidney Failure
| Article | Year |
|---|---|
Incident hyperkalemia may be an independent therapeutic target in low ejection fraction heart failure patients: insights from the HEAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Delivery Systems; Female; Follow- | 2014 |
Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Drugs, Chinese Herbal; Humans; Kidney; Losartan; Renal Insu | 2015 |
The pharmacokinetics of losartan in renal insufficiency.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Blood Pressure; Creatinine; Dose-Response Relation | 1995 |
High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
Efficacy and safety of losartan in patients with proteinuria.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Disease Progression; Female; Humans; Losartan; Male; | 2002 |
Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment.
Topics: Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Drug Therapy, Combination; | 2003 |
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Drug | 2005 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function.
Topics: Antihypertensive Agents; Captopril; Double-Blind Method; Humans; Hypertension; Losartan; Middle Aged | 1999 |
29 other studies available for losartan and Kidney Failure
| Article | Year |
|---|---|
Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarker | 2018 |
Pharmacological inhibition of TRPV4 channels protects against ischemia-reperfusion-induced renal insufficiency in neonatal pigs.
Topics: Animals; Animals, Newborn; Blood Pressure; Glomerular Filtration Rate; Ischemia; Kidney; Losartan; M | 2019 |
Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart Failure; Kidney; Kidney Function Tests; Losa | 2013 |
Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Cellular Senescence; Gene Expression; Insulin-Like Growth | 2013 |
Increased expression of (pro)renin receptor does not cause hypertension or cardiac and renal fibrosis in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Female; Fibrosis; Heart Ventricles; H | 2014 |
Losartan and Sodium Nitroprusside Effectively Protect against Renal Impairments after Ischemia and Reperfusion in Rats.
Topics: Adenosine Triphosphatases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arginin | 2015 |
Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Ce | 2017 |
Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Body We | 2009 |
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasenta | 2009 |
Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Azotemia | 2011 |
Effect of experimental renal failure on the pharmacokinetics of losartan in rats.
Topics: Animals; Losartan; Male; Microsomes, Liver; Rats; Rats, Wistar; Renal Insufficiency; Uranyl Nitrate | 2002 |
Progression of renal failure delayed by use of losartan in a case of IgA nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Creatinine; Disea | 2002 |
Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Glome | 2003 |
AT1 receptor blockade improves vasorelaxation in experimental renal failure.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Atrial Natriuretic Factor; Blood Pressure; Endothe | 2003 |
Evaluation of a technique of inducing hypertensive renal insufficiency in cats.
Topics: Amlodipine; Analysis of Variance; Animals; Blood Pressure; Blood Pressure Determination; Cat Disease | 2004 |
ATRA therapy restores normal renal function and renal reserve and prevents renal failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Creatinine; Disease Progres | 2005 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis.
Topics: Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Dose-Response Re | 2005 |
Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; C | 2005 |
Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atherosclerosis; Choleste | 2006 |
Losartan, an angiotensin-II receptor antagonist, retards the progression of advanced renal insufficiency.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine; | 2006 |
Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Humans; Hypertension; Inf | 2006 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1993 |
Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Anaemia in dialysis patients as a side-effect of sartanes.
Topics: Anemia; Antihypertensive Agents; Biphenyl Compounds; Hemoglobins; Humans; Irbesartan; Kidney Transpl | 1998 |
Effect of angiotensin II blockade on renal injury in mineralocorticoid-salt hypertension.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2000 |
Losartan use in mild to moderate hypertension--adverse effects in moderate to severe renal failure.
Topics: Antihypertensive Agents; Humans; Hypertension; Losartan; Renal Insufficiency | 2001 |
Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 5,8,11,14-Eicosatetraynoic Acid; | 2001 |